Evotec is particularly focused on expanding its biologics capabilities to meet increased demand for complex biologics manufacturing and broaden its offerings to customers. We expect the company will ...

Our fair value estimate for narrow-moat Scentre Group is AUD 3.80 per security, derived using a discounted cash flow valuation with a 7.5% weighted average cost of capital. Our valuation implies a ...

Qualtrics CEO Zig Serafin says the most successful people balance their big-picture vision with the ability to do the daily ...